Prediction of paclitaxel sensitivity by CDK1 and CDK2 activity in human breast cancer cells

INTRODUCTION: Paclitaxel is used widely in the treatment of breast cancer. Not all tumors respond to this drug, however, and the characteristics that distinguish resistant tumors from sensitive tumors are not well defined. Activation of the spindle assembly checkpoint is required for paclitaxel-indu...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Satoshi, Torikoshi, Yasuhiro, Takahashi, Takeshi, Yoshida, Tomokazu, Sudo, Tamotsu, Matsushima, Tomoko, Kawasaki, Yuko, Katayama, Aya, Gohda, Keigo, Hortobagyi, Gabriel N, Noguchi, Shinzaburo, Sakai, Toshiyuki, Ishihara, Hideki, Ueno, Naoto T
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687717/
https://www.ncbi.nlm.nih.gov/pubmed/19239702
http://dx.doi.org/10.1186/bcr2231

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2687717/
https://www.ncbi.nlm.nih.gov/pubmed/19239702
http://dx.doi.org/10.1186/bcr2231

Ejemplares similares